The effect of antidepressant drugs on thioacetamide-induced oxidative stress

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 735-744

  Abdel Salam, O M E ^a   Mohammed, N A ^a   Sleem, A A ^a   Farrag, A R ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Antidepressant drugs; Brain; Liver; Oxidative stress; Rat; Thioacetamide

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; FLUOXETINE; GLUTATHIONE; IMIPRAMINE; MALONALDEHYDE; NITRIC OXIDE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIOACETAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN LEVEL; CONTROLLED STUDY; EUTHANASIA; FEMALE; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER INJURY; LIVER LEVEL; LIVER TOXICITY; MALE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ANTIDEPRESSIVE AGENTS; ASPARTATE AMINOTRANSFERASES; BRAIN; FEMALE; FLUOXETINE; GLUTATHIONE; LIVER; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SERTRALINE; THIOACETAMIDE;

EID: 84878564072     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. LANG JP, MEYER N, DOFFOEL M. Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients. Encephale 2003; 29: 362-365.
2. COZZI A, ZIGNEGO AL, CARPENDO R, BIAGIOTTI T, ALDINUCCI A, MONTI M, GIANNINI C, ROSSELLI M, LAFFI G, MORONI F. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 2006; 13: 402-408.
3. SCHAFER M, SCHMIDT F, AMANN B, SCHLSSER S, LOESCHKE K, GRUNZE H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42(Suppl 1): 43-45.
4. GLEASON OC, YATES WR, ISBELL MD, PHILIPSEN MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63: 194-198.
5. CAI W, KHAOUSTOV VI, XIE Q, PAN T, LE W, YOFFE B. Interferon-alpha- induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005; 42: 880-887.
6. GIBBONS SS. Antidepressants. In: Pharmacology for the Primary Care Provider (Edmunds MW & Mayhew MS, eds.), Mosby INC, St. Louis, Missouri, USA, 2000, pp. 602-620.
7. PERSKY S, REINUS JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003; 48: 939-944.
8. DESANTY KP, AMABILE CM. Antidepressant-induced liver injury. Ann Pharmacother 2007; 41: 1201-1211.
9. ABDEL SALAM OME, SLEEM AA, SHAFFIE NM. Effect of the selective serotonin reuptake inhibitor fluoxetine on carbon tetrachloride induced hepatic damage in rats. J Pharmacol Toxicol 2006; 1: 395-406
10. ABDEL SALAM OME, SLEEM AA, SHAFEE N. Effect of trazodone and nefazodone on hepatic injury induced by carbon tetrachloride. Drug Discov Ther 2010; 4: 285-297.
11. TER BORG PC, VAN OS E, VAN DEN BROEK WW, HANSEN BE, VAN BUUREN HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004; 4: 13.
12. BROWNING J, COMBES B, MAYO MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2736-2741.
13. MAYO MJ, HANDEM I, SALDANA S, JACOBE H, GETACHEW Y, RUSH AJ. Sertraline as a first-line treatment for cholestatic pruritus.Hepatology 2007; 45: 666-674.
14. JONES EA. Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C. Med Hypotheses 2001; 57: 133-134.
15. ZIGNEGO AL, COZZI A, CARPENEDO R, GIANNINI C, ROSSELLI M, BIAGIOLI T, ALDINUCCI A, LAFFI G, MORONI F. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis 2007; 39(Suppl 1): S107-111.
16. MICHALAK A, ROSE C, BUU PN, BUTTERWORTH RF. Evidence for altered central noradrenergic function in experimental acute liver failure in the rat. Hepatology 1998; 27: 362-368.
17. MICHALAK A, CHATAURET N, BUTTERWORTH RF. Evidence for a serotonin transporter deficit in experimental acute liver failure. Neurochem Int 2001; 38: 163-168.
18. ALBRECHT J, JONES EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999; 170: 138-146.
19. LOZEVA-THOMAS V. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis 2004; 19: 413-420.
20. LOZEVA V, MONTGOMERY JA, TUOMISTO L, ROCHELEAU B, PANNUNZIO M, HUET PM, BUTTERWORTH RF. Increased brain serotonin turnover correlates withthe degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004; 40: 742-748.
21. LUCENA MI, ANDRADE RJ, DE LA CRUZ JP, RODRIGUEZMENDIZABAL M, BLANCO E, SANCHEZ DE LA CUESTA F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 2002; 40: 2-8.
22. NOVO E, PAROLA M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008; 1: 5.
23. FEHÉR J, LENGYEL G. Silymarin in the treatment of chronic liver diseases: Past and future. J Clin Exp Med 2009; 3: 403-413.
24. HAUSSINGER D, SCHLIESS F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-1165.
25. CHUNG YC, KIM SR, PARK JY, CHUNG ES, PARK KW, WON SY, BOK E, JIN M, PARK ES, YOON SH, KO HW, KIM YS, JIN BK. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011; 60: 963-974.
26. LEE CH, PARK JH, YOO KY, CHOI JH, HWANG IK, RYU PD, KIM DH, KWON YG, KIM YM, WON MH. Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol 2011; 229: 450-459.
27. WANG T, FONTENOT RD, SONI MG, BUCCI TJ, MEHENDALE HM. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats.Toxicol Appl Pharmacol 2000; 166: 92-100.
28. BRUCK R, GENINA O, AEED S, ALEXIEV R, NAGLER A, AVNI Y, PINES M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33: 379-386.
29. PAGET GE, BARNES JM. Toxicity testing. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities pharmacometics. Academic Press, London, 1964, pp. 1-135.
30. RUIZ-LARREA MB, LEAL AM, LIZA M, LACORT M, DE GROOT H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids 1994; 59: 383-388.
31. ELLMAN GL. Tissue sulfhydryl groups. Arch Biochem 1959; 82: 70-77.
32. Moshage H, Kok B, Huizenga JR. Nitrite and nitrate determination in plasma: A critical evaluation. Clin Chem 1995; 41: 892-896.
33. CROWLEY LV. The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem 1967; 13: 482-487.
34. BELFIELD A, GOLDBERG DM. Revised assay for serum phenyl phosphatase activity using 4- amino-antipyrine. Enzyme 1971; 12: 561-573.
35. GUTTERIDGE JMC. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clinc Chem 1995; 41: 1819-1828.
36. SCHMIDT AJ, HEISER P, HEMMETER UM, KRIEG JC, VEDDER H. Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U- 937 cells. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1567-1573.
37. LOBATO KR, CARDOSO CC, BINFARÉ RW, BUDNI J, WAGNER CL, BROCARDO PS, DE SOUZA LF, BROCARDO C, FLESCH S, FREITAS AE, DAFRÉ AL, RODRIGUES AL. alpha- Tocopherol administration produces an antidepressant- like effect in predictive animal models of depression. Behav Brain Res 2010; 209: 249-259.
38. CZUCZEJKO J, ZACHARA BA, STAUBACH-TOPCZEWSKA E, HALOTA V, K DZIORA J. Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases.Acta Biochim Pol 2003; 50: 1147-1154.
39. SCHULZ JB, LINDENAU J, SEYFRIED J, DICHGANS J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267: 4904-4911.
40. NG F, BERK M, DEAN O, BUSH AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-876.
41. MONCADA S, BOLANOS JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676-1689.
42. DAWSON VL, DAWSON TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996; 10: 179-190.
43. MONCADA S, PALMER RMJ, HIGGS EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
44. JOCA SR, GUIMARÃES FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacol (Berl) 2006; 185: 298-305.
45. HARKIN A, CONNOR TJ, BURNS MP, KELLY JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004; 14: 274-281.
46. KRASS M, WEGENER G, VASAR E, VOLKE V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218: 57-63.
47. GUARNER C, SORIANO G, TOMAS A, BULBENA O, NOVELLA MT, BALANZO J, VILARDELL F, MOURELLE M, MONCADA S. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-1143.
48. PÂRVU AE, NEGREAN V, PLE CA-MANEA L, COSMA A, DR GHICI A, UIF LEAN A, MOLDOVAN R. Nitric oxide in patients with chronic liver diseases. Rom J Gastroenterol 2005; 14: 225-230.
49. HARVEY BH, RETIEF R, KORFF A, WEGENER G. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. Metab Brain Dis 2006; 21: 211-220.
50. LIU D, WANG Z, LIU S, WANG F, ZHAO S, HAO A. Antiinflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 2011; 61: 592-599.
51. HA E, JUNG KH, CHOE BK, BAE JH, SHIN DH, YIM SV, BAIK HH. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 2006; 397: 185-189.
52. HORIKAWA H, KATO TA, MIZOGUCHI Y, MONJI A, SEKI Y, OHKURI T, GOTOH L, YONAHA M, UEDA T, HASHIOKA S, KANBA S. Inhibitory effects of SSRIs on IFN-? induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1306-1316.
53. FULLER RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163-167.
54. POZZI L, INVERNIZZI R, GARAVAGLIA C, SAMANIN R. Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J Neurochem 1999; 73: 1051-1057.
55. BYMASTER FP, ZHANG W, CARTER PA, SHAW J, CHERNET E, PHEBUS L, WONG DT, PERRY KW. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002; 160: 353-361.
56. KITAICHI Y, INOUE T, NAKAGAWA S, BOKU S, KAKUTA A, IZUMI T, KOYAMA T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010; 647: 90-96.
57. FELTON TM, KANG TB, HJORTH S, AUERBACH SB. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 297-305.